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Abstract
Virophages are satellite-like dsDNA viruses that parasitize giant viruses of the family
Mimiviridae. Mavirus is the second virophage discovered that associates with its host virus
Cafeteria roenbergensis Virus (CroV). When co-infecting their common host cell Cafeteria
roenbergensis, a marine zooplankton that is widely spread throughout the oceans, mavirus will
inhibit CroV’s replication. In addition, mavirus was shown to share high similarities to the
Maverick/Polinton eukaryotic DNA transposons. A coding sequence in mavirus genome (MV02)
reveals high homology to retroviral integrases such as those found in HIVs. The putative
integrase MV02 is predicted to integrate mavirus DNA into the host genome. In order to
characterize MV02 and prove it is indeed an integrase, large amounts of protein need to be
obtained and three functional aspects must be studied that include: DNA binding, DNA
processing, and DNA strand transfer. In this study, large amount of recombinant MV02 has been
expressed and purified to high homogeneity. The recombinant MV02 has been tested for its
DNA binding using chromatographic techniques and gel shift assays. These experiments build
the foundation for future structural studies as well as further functional analysis such as testing
DNA processing and strand transfer capabilities of recombinant MV02. Proving MV02 is an
integrase will not only reveal an aspect of the virophage infection process, but will also shed
light on the evolutionary relationship between the mavirus and the Maverick/Polinton
transposons. Due to high similarity between MV02 and retroviral integrase and limited structural
and functional knowledge of the latter, new information obtained by studying mavirus integrase
will shed new insights for drug development against AIDS.
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Chapter 1: Introduction
1.1. Satellite Viruses vs Virophages
The Satellite Tobacco Mosaic Virus was the first satellite virus to be discovered, showing
that there exist “satellite” particles that could only replicate with the help of a “host” virus. This
discovery led to the study of many satellite viruses found in bacteria [1], animals [2, 3], and
plants [2-7]. Satellite viruses have been defined as subviral agents composed of either ssDNA or
ssRNA encapsulated by their own encoded capsid and do not encode their own transcription
machinery or any other functional proteins, but rely on their host virus for DNA replication
and/or RNA transcription [3, 5-7]. Satellite viruses do not share genomic similarities to the host
virus and are not required for the host virus to replicate [6, 7]. Studies have shown that there are
satellite viruses that can be beneficial to the host, as they can reduce the accumulation of the host
virus RNA, resulting in less severe symptoms [6, 7]. It was not until the discovery of the Sputnik
virus that revealed satellite-like viruses that completely inhibit the replication of the host virus
while both of them infect the host at the same time [3, 8]. The Sputnik virus challenged the
traditional definition of satellite viruses as they contain dsDNA and encode multiple functional
proteins including those that replicate viral DNA [3, 8]. This parasitic satellite-like virus has thus
been coined the term “virophage” because of its inhibitory effect to the host virus. More
virophages have been discovered later as listed in Table 1.1 [3, 8-11].
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Table 1.1: List of known virophages, their host virus, and their host to date
Virophage

Host Virus

Host

Sputnik Virus

Mamavirus

Acanthamoeba polyphaga

Mavirus

Cafeteria roenbergensis virus

Cafeteria roenbergensis

Organic Lake Virophage*

Unknown Organic Lake
phycodnavirus

Unknown Organic Lake host

Zamilon Virophage*

Mont1

Acanthamoeba polyphaga

*Assumed to be virophages, but require more studies to confirm
1.2. Importance of Host Giant Virus Virion Factories for Virophage Replication
The 4 virophages discovered all have host viruses that are known as giant viruses (Table
1) [8-11]. Giant viruses were first discovered in 2003 with the discovery of the Acanthamoeba
polyphaga mimivirus (APMV) after it was thought to be a small Gram-positive coccus due to its
physical size (500nm diameter) and shape [12]. Once it was realized that viruses are no longer
limited to being defined as pathogens that can be filtered through 0.2-0.3µm pore filters,
researchers were able to discover and isolate other giant viruses [12-15]. With the discovery of
multiple giant viruses, it was seen that several of them have the capability to form virion
factories in the host cell when they replicate [3, 8, 9, 11, 13, 16, 17]. Virion factories are
complex intracellular compartments where viral and host components accumulate to undergo
viral replication and/or assembly [16]. Due to the complex signaling requirements needed to
induce the formation of virion factories, not all viruses, including virophages, could form them
[16]. Virophage replication and assembly occurs in the virion factories that giant viruses form,
where the virophage hijacks the transcription machinery of the host giant virus and replicates
with the energy and translation capabilities of the host [3, 8, 9, 11, 13, 16, 17]. Upon the
virophage hijacking the components of the virion factories, it was seen for both the Sputnik virus
and the mavirus that the replication of the host giant virus was inhibited (hence why they were
termed virophages and not traditional satellite viruses) [8, 9]. The Organic lake virophage has
2

only been detected metagenomically; therefore, virophage replication and assembly has not been
studied [10]. The Zamilon virophage is assumed to be a virophage, and was seen to replicate in
the host giant virus virion factory. Due to the Zamilon Virophage not inhibiting the host giant
virus replication, more studies are required to confirm if it truly is a virophage [11]. Interestingly,
it has been observed that virophages do not require their host giant virus for infection, but do
require the virion factories formed by the giant viruses for virophage replication and assembly
(Fig. 1.1) [8, 9, 11].
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Figure 1.1: Virophage, host virus, and cellular host.
A) Host cell. B) Virophages do not require their host giant virus for infection, but cannot
replicate without them. C) Giant virus infection leads to the assembly of virion factories. Once
virion factories are established, giant viruses replicate and assemble. Giant viruses are released
by host lysis and can infect a new host. D) Virophages hijack the components of the virion
factories leading to their replication and assembly. Virophage replication will inhibit giant host
virus replication. Hosts will lyse and release replicated virophage, leading them to repeat the
whole process with or without giant virus infection.
4

1.3. Integration of Mavirus DNA into the Host Genome
The mavirus, a dsDNA virus, is the second virophage discovered and is known to
parasitize the giant Cafeteria roenbergensis Virus (CroV) while they both co-infect their host
Cafeteria roenbergensis, a marine zooplankton [9, 15, 17]. The mavirus’s genome was
sequenced and found to resemble Maverick/Polinton (MP) eukaryotic DNA transposable
elements (TEs) [9]. The gene for the retroviral integrase (rve-INT) is one of the most conserved
coding sequences found within MP TEs [9, 18, 19]. One of the mavirus ORFs, MV02, is
predicted to be an rve-INT resembling mostly to those encoded by MP TEs [9]. The main
function of the rve-INT is to integrate viral DNA into host cell genome with the use of a catalytic
domain and a DNA binding domain. Upon viral and host DNA binding, DNA integration occurs
in two major steps: DNA processing and DNA strand transfer. DNA processing occurs when
integrase conducts its 3’-end exonuclease activities to the viral DNA, exposing 3’-hydroxyls
(normally after a dinucleotide CA sequence in HIV-1 integrase). The processed viral DNA is
then inserted into the host DNA through strand transfer. The nick between viral and host DNA
will then be repaired by cellular DNA repair mechanism (Fig. 1.2) [20-24].
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Figure 1.2: Integration of viral and host DNA by a retroviral integrase.
Integrase binds viral DNA. 3’-end processing occurs at a conserved CA dinucleotide
sequence on the 3’-end of the viral DNA strand. Viral DNA strand transfer into host DNA is
utilized by the integrase. Once viral DNA is attached, integrase releases the DNA and the host
polymerase repairs the nucleotide gap, thus completing viral DNA integration to the host DNA.
1.4. Project Goal
The goal of this project is to characterize MV02, the putative integrase from mavirus.
Particularly, in this study, MV02 has been cloned, expressed, and purified as a recombinant
protein. Its DNA binding capability has been verified by various biochemical methods. Studying
MV02 is important because it will reveal the exact mechanism of how the mavirus integrates its
DNA into the genome of its cellular host, C. roenbergensis. Mavirus integration into host
genome can be seen as an evolutionary step as both organisms are benefitted: mavirus DNA
being replicated and transferred through generations of the host while C. roenbergensis gains
community immunity to CroV. Another aspect of mavirus integration into C. roenbergensis
6

genome can be seen as a way to control the CroV population. Studies have shown that viruses
play a critical role in the marine ecological and biogeochemical systems as they keep the hosts
from overpopulating [25]. The role of the virophage is assumed to ensure that the host virus is
prevented from overpopulating; otherwise, the cellular host population could be wiped out
completely. Studying different aspects of the virophage infection and replication cycles can shed
light on the evolutionary relationships between the virophage, host virus, and host and their
effects in the marine ecological and biogeochemical systems.
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Chapter 2: Materials and Methods
2.1. Recombinant MV02 Design and Expression
2.1.1. MV02 Expression Construct
MV02 was codon optimized for bacterial expression and synthesized by GenScript Inc.
The synthesized DNA was cloned into pCold TF (Takara) using restriction enzymes NdeI and
XhoI at the 5’-end and 3’end, respectively. MV02 was designed to be expressed as a fusion
protein with a ribosome associated bacterial chaperone called trigger factor (TF). The addition of
TF serves two purposes: to assist in protein folding and to solubilize recombinant protein. The
TF tag can be removed with the use of thrombin at a cleavage site designed between TF and
MV02. A 6X Histidine tag was engineered at the 3’ end of MV02 to ensure that only intact
recombinant protein will be purified by affinity chromatography. The ligated plasmid was
transformed into high-copy E. coli Mach 1 strain (Thermo Scientific), a fast grow strain with
high copy number of plasmid, to obtain plasmid for further transformation and sequencing
verification. Purified and sequence verified plasmids were then transformed into E. coli BL21
(DE3) pLysS strain (Novagen) for protein expression.
2.1.1. Recombinant TF-MV02 Expression
Colonies of transformed BL21 were grown on an LB agar plate containing 100µg/ml
ampicillin. Individual colonies were picked and grown in 10mL of LB media with 100µg/ml
ampicillin overnight at 37ºC with 160 RPM shaking as a pre-culture. The pre-culture was diluted
1:500 times into 4 batches of 1L of LB media containing 100µg/ml ampicillin and grown at 37ºC
with 160 RPM shaking. Once the culture reached an OD600 of 0.5, the temperature setting was
reduced to 15ºC while the culture was continued to grow with 160 RPM shaking. After the
temperature reached 15ºC, shaking was stopped for 30 minutes. IPTG was then added to a final
concentration of 1mM and shaking at 160RPM was restarted. Protein was expressed for 22
hours.
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2.2. Purification of Recombinant TF-MV02
2.2.1 Affinity Chromatography
After 22-hour expression, 4L of bacterial culture was centrifuged at 5,000xg for 20
minutes. Supernatant was removed and the pellets were resuspended with lysis buffer (50mM
Trizma Base; 300mM NaCl; 10mM Imidazole; 0.02% NaN3; pH 7.5). After adding 10µg/mL of
lysozyme to resuspended lysates, they were slowly frozen at -20ºC. Frozen lysates were then
freeze/thawed 3 times to release proteins from the cell. After thawing the last time, 20µg/mL
DNase and 1mM MgCl2 were added to the lysate and incubated on ice for 20 minutes with gentle
rocking. Centrifugation at 31,000xg followed by filtration with 0.45µm filters was performed on
lysate to remove large insoluble debris from cell lysate. 50 to 90mL lysate (equivalent of 1.5L
cell culture) was loaded to a 5mL HisTrap Hp column (GE catalog #17-5247-01) preequilibrated with lysis buffer at a flowrate of 2mL/min. After loading, the flowrate was increased
to 3mL/min and 5 column volumes of lysis buffer were used to remove unbound proteins. Then,
10 column volumes of a 100mM imidazole wash was applied to the affinity column to remove
unspecific bound protein by mixing lysis buffer with elution buffer (50mM Trizma Base;
150mM NaCl; 500mM Imidazole; 0.02% NaN3; pH 7.5). Recombinant TF-MV02 was eluted
with 150mM imidazole for 5-8 column volumes, depending on when the chromatogram UV peak
plateaued. The 150mM imidazole elution was desalted immediately after affinity
chromatography using a 53mL HiPrep 26/10 desalting column (GE catalog #17-5087-01) with
desalting buffer (50mM Trizma Base; 100mM NaCl; 0.02% NaN3; pH 8.0). A Pierce BCA
Protein Assay kit (Thermo Scientific catalog #23225) determined the average concentration of
desalted 150mM imidazole to be 300µg/mL, yielding an average of 18mg of recombinant TFMV02 per 1.5L of culture.
2.2.2. Ion-Exchange Chromatography
Ion-exchange chromatography was determined to be the next step of purification due to
contaminants still being present after affinity chromatography. Once the pI of TF-MV02 was
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calculated to be 5.6 using various online proteomic tools, anion-exchange chromatography was
performed at pH 8.0. A volume of 30mL worth of 300µg/mL of the desalted eluent from affinity
chromatography was concentrated and buffer exchanged from desalting buffer to ion-exchange
buffer A (20mM Trizma Base; 20mM NaCl; 0.02% NaN3; pH 8.0) to a final volume of 5mL
using a 6mL Vivaspin 6 MWCO 30,000 concentrator (GE catalog #28932317). The concentrated
sample was loaded to a 5mL HiTrap Q HP anion-exchange column (GE #17-1153-01) preequilibrated with ion-exchange buffer A at a flowrate of 1mL/min. Contaminants were washed
away using a linear gradient of 20mM NaCl to 220mM NaCl by mixing ion-exchange buffer A
with ion-exchange buffer B (20mM Trizma Base; 1M NaCl; 0.02% NaN3; pH 8.0). Recombinant
TF-MV02 was eluted using a linear gradient of 220mM NaCl to 350mM NaCl.
2.2.3. Size-Exclusion Chromatography
The ion-exchange chromatographically purified recombinant TF-MV02 was immediately
concentrated to 5mL using aforementioned 6mL Vivaspin 6 MWCO 30,000 concentrator (GE
catalog #28932317). The concentrated sample was loaded to a 320mL HiLoad 16/60 Superdex
200 size-exclusion column (GE catalog #28-9893-95) pre-equilibrated with size-exclusion buffer
(50mM Trizma Base; 100mM NaCl; 0.02% NaN3; pH 8.0). Pure recombinant TF-MV02 was
collected at the volume of 175ml as a monomer. The concentration of the size-exclusion eluent
was averaged to be ~500µg/mL based on aforementioned Pierce BCA Protein Assay kit (Thermo
Scientific catalog #23225). Size-exclusion chromatography (SEC) was also utilized for detecting
recombinant TF-MV02 conformational change upon binding to DNA.
2.3. Thrombin Digest Optimization and Purification of Recombinant MV02
A batch of purified recombinant TF-MV02 was incubated for 9 hours at room
temperature with different concentrations of thrombin for digest optimization. After thrombin
concentration optimization, a separate batch of purified recombinant TF-MV02 was diluted to
300µg/mL and incubated with 3mU/mL of thrombin at room temperature for different time
periods ranging between 4-10 hours. The thrombin digest reactions were quenched with 1mM
10

PMSF. After thrombin digest optimization, affinity chromatography was conducted due to the
6X His tag being expressed at the C-terminal of MV02, allowing TF to be removed. A similar
affinity chromatography protocol aforementioned above was followed with the addition of a
90mM imidazole wash step and a 200mM imidazole elution step. SEC following the same
aforementioned protocol above was utilized to separate undigested recombinant TF-MV02 from
TF removed recombinant MV02.
2.4. Protein-DNA Interaction Studies of Recombinant TF-MV02
2.4.1. Heparin Chromatography on Recombinant Purified TF-MV02
Purified recombinant TF-MV02 was concentrated to 4mg/mL to conduct various in vitro
DNA binding assays with the use of aforementioned 6mL Vivaspin 6 MWCO 30,000
concentrator (GE catalog #28932317). 2.5mL of ~500µg/mL purified recombinant TF-MV02
was loaded to a 1mL HiTrap Heparin HP column (GE catalog #17-0406-01) pre-equilibrated
with heparin buffer A (20mM Trizma Base; 0.02% NaN3; pH 8.0). Bound proteins were eluted
with a step-gradient of 20mM NaCl to 1M NaCl by mixing heparin buffer A and heparin buffer
B (20mM Trizma Base; 2M NaCl; 0.02% NaN3; pH 8.0).
2.4.2. Agarose Gel Shift Assay
An agarose gel shift assay was designed to test DNA binding capabilities and specificities
of recombinant TF-MV02. Multiple DNA oligoes (Table 2) were designed from host and
virophage sequences and synthesized by Sigma-Aldrich Co. As DNA controls, a random
palindrome sequence and a random double-stranded sequence were also designed and
synthesized. As protein controls, a second recombinant protein that contained TF and a TF tag
removed recombinant MV02 were purified. DNA and protein were stained individually with EZ
Vision Three Dye (Amresco) and as a protein with DNA mixture at a 1:4 mole ratio,
respectively. A separate set of TF tagged removed recombinant MV02 sample was incubated
with DNA overnight and left unstained. A 2% agarose gel (2% agarose; 1X TBE) was prepared
to account for the short 50 base pair oligoes. The stained recombinant TF-MV02, TF tagged
11

removed MV02, and DNA samples were loaded to the 2% agarose gel and ran at 160V for 10-15
minutes at pH 8.0. The 2% agarose gels were assessed with a UV source (Alpha Innotech) for
DNA shift and then were stained with Coomassie Brilliant BlueR (Sigma-Aldrich CAS #610459-2) overnight. The Coomassie Brilliant BlueR stained gels were then destained with destaining
solution (10% Acetic Acid; 5% Ethanol) until protein bands could be seen clearly. The overnight
unstained TF tag removed recombinant MV02 was ran at same conditions except at a pH of 9.2
and ethidium bromide staining was used to detect DNA shift.
Table 2.1: Oligoes designed for agarose gel shift assay
DNA Oligo

Sequence

5’- ATCCACCACAGCCTCCCCTTTTA
TGCATAAAAGGGGAGGCTGTGGTGGAT
-3’

Host Palindromic Oligo

(H in Fig. 3.12 Lanes 2 and 3)

5’-CCCATTTTTTAATTAAATCTCTA
GGACAAAATTAAAAAATGGG-3’

Virophage Palindromic Oligo

(V in Fig. 3.12 Lanes 4 and 5)

5’-CGCATTCCTCTAGACCTTACTTG
ACGTCAAGTAAGGTCTAGAGGAATGCG
-3’
5’-AGGCTAGAAAATAATGCTGAAAC
CGTCCCCCAAGCGTAGAGAATACCATT3’
5’-AATGGTATTCTCTACGCTTGGGG
GACGGTTTCAGCATTATTTTCTAGCCT3’

Random Palindromic Oligo

(P in Fig. 3.12 Lanes 6 and 7)
Random Sense Oligo*

(One of the ds in Fig. 14 Lanes 8 and 9)
(Also ss in Fig. 3.12 Lanes 10 and 11)
Random Antisense Oligo*
(One of the ds in Fig. 3.12 Lanes 8 and 9)

* Will be used together to form dsDNA. All the other oligoes will be used as ssDNA, but will
form dsDNA as stem-loop structure.
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Chapter 3: Results
3.1. Successful Expression and Purification of Recombinant TF-MV02
Recombinant TF-MV02 was cloned and expressed successfully (Fig. 3.1). Affinity
chromatography purified recombinant TF-MV02 to >85% homogeneity (Fig. 3.2). Anionexchange chromatography further purified recombinant TF-MV02 to >95% homogeneity (Fig.
3.3). SEC resulted in recombinant TF-MV02 to >99% homogeneity (Fig 3.4) and showed
conformational change when recombinant TF-MV02 binds to DNA (Fig. 3.5).

Figure 3.1: SDS-PAGE of recombinant TF-MV02 expression.
Recombinant TF-MV02 supernatant (S) and pellet (P) from bacterial culture with and
without IPTG induction are shown. The third lane is the molecular weight (MW) marker. The
arrow on the left points to the expected size of recombinant TF-MV02 (91kDa).
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Figure 3.2: SDS-PAGE of purification and desalting of recombinant TF-MV02 using affinity and
desalting chromatography, respectively.
SDS-PAGE shows molecular weight (MW) marker, crude sample, flow through (FT),
10mM imidazole wash, 100mM imidazole wash, two 150mM imidazole elution fractions, and
two desalted fractions. The arrow on the right points to the expected size of recombinant TFMV02 (91kDa). Lane labeled as x is an empty lane.
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Figure 3.3: Chromatogram and SDS-PAGE of purification of recombinant TF-MV02 using
anion-exchange.
Of the 2 peaks; the first one represents contaminants and second peak represents purified
recombinant TF-MV02 (91kDa). The light green line represents the percentage of ion-exchange
buffer B used. The contaminants are labeled appropriately and the eluent of the second peak is
shown in an SDS-PAGE to the side.
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Figure 3.4: Chromatogram and SDS-PAGE of purification of recombinant TF-MV02 using SEC.
Of the 2 peaks; the first one represents the recombinant TF-MV02 (93kDa) at ~175mL
(equivalent to ~100kDa) and the second peak represents contaminants at ~200mL (equivalent to
~50kDa). The respective SDS-PAGEs are shown to the sides or top of the peaks with arrow
indications.
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Figure 3.5: Multiple peaks being displayed in the chromatogram and SDS-PAGE show different
conformations of recombinant TF-MV02 bound DNA.
Peaks from left to right: aggregated conformation at ~120mL (equivalent to ~>600kDa), dimeric
conformation at ~150mL (equivalent to ~200kDa), monomeric conformation at ~175mL
(equivalent to ~50kDa), possible loosely associated DNA at ~190mL, and possible unbound
DNA ~210mL. The respective SDS-PAGE is shown next to the side of the monomeric peak,
while arrows point to the other conformations or DNA.
3.2. Thrombin Digestion and Purification Optimization
Digestion of TF-MV02 was conducted with different concentrations of thrombin for 9
hours and SDS-PAGE displayed increasing digestion with higher concentration of thrombin (Fig.
3.6). However, with higher concentrations of thrombin, unwanted degradation also began to
appear. Time-scale digestion with 3mU/mL showed slight increase of digestion product, but
digestion was saturated at 9 hours (Fig. 3.7). After digestion conditions were optimized, large17

scale thrombin digested recombinant TF-MV02 was purified with affinity chromatography to
remove TF (Fig. 3.8). SEC was utilized to separate undigested recombinant TF-MV02 from
recombinant MV02 (Fig. 3.9).

Figure 3.6: Thrombin digestion optimization with increasing concentrations of thrombin.
Lane 1 is molecular weight (MW), Lane 2 shows undigested recombinant TF-MV02. Lane 3 to 5
are digested recombinant TF-MV02 with increasing amounts of thrombin (3mU/mL, 6mU/mL,
and 9mU/mL), respectively.
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Figure 3.7: Thrombin digestion optimization with increasing time.
Lane 1 is molecular weight (MW). Lane 2 shows undigested recombinant TF-MV02.
Lanes 3 to 9 are digested TF-MV02 incubated with thrombin between 4 – 10 hours (hrs),
respectively.
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Figure 3.8: Affinity chromatography on digested TF-MV02.
SDS-PAGE shows molecular weight (MW), digested recombinant TF-MV02, two
fractions of flowthrough (FT), 90mM imidazole wash, 100mM wash, two fractions of 150mM
wash, and two fractions of 200mM elutions, respectively.
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Figure 3.9: Chromatogram and SDS-PAGE of purification of recombinant MV02 using SEC to
remove undigested recombinant TF-MV02.
Of the 2 peaks; the first one represents a mixture of undigested recombinant TF-MV02
(93kDa) and recombinant MV02 (43kDa) at ~175mL (equivalent to ~100kDa) and the second
peak represents purified recombinant MV02 (43kDa) at ~200mL (equivalent to ~50kDa). The
respective SDS-PAGEs are shown at the top and side of the peaks.
3.3. In Vitro DNA Binding Assays Show Recombinant TF-MV02 Affinity to DNA
Heparin has been used to test for general DNA binding due to its structural similarity to
DNA and its negative charge [26-28]. Heparin chromatography showed recombinant TF-MV02
has a high affinity to heparin, requiring 800mM NaCl for elution (Fig. 3.10). Agarose gel shift
assays are used to show if binding occurs between protein and DNA [29]. Multiple agarose gel
shift assays were used to test recombinant TF-MV02 DNA binding capabilities. Initial agarose
gel shift assays demonstrate that recombinant TF-MV02 has an affinity for palindromic oligoes
(Fig. 3.11). The negative control of a TF fused viral protein [30] shows that the TF tag doesn’t
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bind to DNA. Further agarose gel shift assay demonstrated that recombinant TF-MV02 can bind
to all types of double-stranded DNA (not sequence specific) including: palindromic host DNA,
palindromic virophage DNA, random palindromic DNA, random double-stranded DNA.
However, single-stranded DNA binding could not be observed, possibly due to the DNA
fluorescent dye (Amresco) only interacting with double-stranded and palindromic DNA that
forms double-stranded stem-loop (Fig. 3.12). DNA was added to TF tag removed recombinant
MV02 and the mixture incubated at room temperature overnight. Ethidium bromide was used to
detect DNA shift, and Coomasie Brilliant BlueR staining revealed protein smearing possibly due
to the pI of recombinant MV02 (8.9) being close to the pH of the buffer (9.2) (Fig. 3.13). The
high pH was needed to ensure that both protein and DNA have a negative charge to migrate to
the cathode in electrophoresis. It will be too difficult to use buffer with higher pH, because the
high pH will destabilize the agarose polymer.

Figure 3.10: Chromatogram and SDS-PAGE of recombinant TF-MV02/DNA binding test using
heparin chromatography.
Step-gradient of heparin buffer B is represented by the light green line. The peak
represents recombinant TF-MV02. The respective SDS-PAGE is shown to the side of the peak.
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Figure 3.11: Recombinant TF-MV02/DNA interactions displayed by agarose gel shift assay.
DNA, recombinant TF-MV02, and recombinant TF-GAM1 (negative control) are shown
either alone or as a mixture using a 1:4 (DNA:protein) mole ratio, labeled respectively above
their lanes. (A) Agarose gel was stained by fluorescent DNA-binding dye to show DNA; (B) The
same gel was stained by Coomassie Brilliant BlueR dye to show protein.

Figure 3.12: Agarose gel (2%) shift assay showing recombinant TF- MV02 binds to multiple
types of oligoes.
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The different types of oligoes from Table 2.1 are shown either alone or with recombinant
TF-MV02 as a 1:4 (DNA:Protein) molar mixture as described above their respective lanes.
Marker represents DNA marker. DNA types are represented by the following abbreviations: H =
host DNA, V = virophage DNA, P = palindromic DNA, dsDNA = double-stranded DNA, and
ssDNA = single-stranded DNA.

Figure 3.13: TF tag removed recombinant MV02/DNA interaction displayed by agarose gel shift
assay.
DNA is shown either alone or as a mixture with TF tag removed recombinant MV02
using a 1:4 (DNA:protein) mole ratio, labeled respectively above their lanes. (A) Agarose gel
was stained by ethidium bromide to show DNA; (B) The same gel was stained by Coomassie
Brilliant BlueR dye to show protein.
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Chapter 4: Discussion
4.1. Conformational Change Revealed by SEC
Up to date, only one DNA bound recombinant integrase has had its atomic structure
solved [31, 32]. Montaño et al. compared solved atomic structures of the integrase along with a
transposase and two recombinases that resemble integrases. They revealed that all these enzymes
form multimer complexes upon binding to DNA that promote catalysis in trans (Fig. 4.1), which
means DNA will bind across different enzymes in the multimeric complex and the DNA bound
to the DNA binding domain in one enzyme will be processed by the catalytic domain of a
different enzyme in the complex (Fig. 4.1) [32]. SEC of DNA bound recombinant TF-MV02
displayed dimer formation (Fig. 3.5), which is consistent with current knowledge of integrase,
indicating recombinant TF-MV02 is very possible an integrase that catalyzes in trans.

Figure 4.1: In trans catalysis observed in integrase and related enzymes.
Integrases are mainly composed of two domains: a DNA binding domain (bottom half)
and a catalytic domain (top half). In trans catalysis is described as when integrase binds DNA
25

with its DNA binding domain and integrase’ catalysis the DNA with its catalytic domain, vice
versa. This process requires multimers of integrases to form. Above it is shown that a dimer is
formed between integrase and integrase’. The star represents the catalysis by the catalytic
domain.
4.2. Recombinant TF-MV02 has Nonspecific DNA Binding
The c-terminal domain of MV02 consist of a conserved chromatin binding domain that
has been shown experimentally to have nonspecific DNA capabilities [20]. This nonspecific
binding prediction is consistent with observation in the heparin chromatography as well as in
agarose gel shift assay with various DNA (Table 2.1, Fig. 3.12).
4.3. Purified Recombinant MV02 Agarose Gel Shift Assays Unrepeatable
TF is a protein chaperon that binds to translating ribosomes in E. coli [33]. The binding
of ribosomes opens up the possibility of TF binding to DNA analogs of mRNA [34]. TF’s
primary purpose is to solubilize and properly fold recombinant protein [33]. Another viral
protein, GAM1, expressed in our group using the same pCold TF system has shown that TF can
have inhibitory effects on enzyme activity of recombinant protein [30]. TF-GAM1 was prepared
to test if the recombinant protein will bind to DNA. Agarose gel shift assay excluded the
possibility of TF binding to DNA (Fig. 3.10). pCold TF vector has a thrombin recognition
sequence between TF and target protein which can be used to remove the TF tag. However, after
removing the TF tag, the recombinant protein has a high pI (8.9) and we had difficulties to use
cleaved MV02 for agarose gel shifting assay. The recombinant TF-MV02 fused protein has a pI
of 5.6 and allowed the recombinant protein to be migrated to cathode in agarose gel
electrophoresis using a pH 8.0 running buffer. TF removal yielded pure recombinant MV02 (Fig.
11). By incubating TF tag removed recombinant MV02 with DNA at room temperature
overnight, agarose gel shift assay displayed protein/DNA interaction may be intact but
recombinant protein was smeared through the gel possibly due to recombinant protein pI (8.9),
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just being slightly lower than the agarose gel shift assay buffer pH (9.2) (Fig. 12). The
experiment was repeated many times, but deemed unrepeatable due to the pH being out of the
buffering range and anything higher than pH 9.2 led to melting of the agarose.
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Chapter 5: Conclusion and Future Work
Recombinant MV02 purification has been optimized with and without a TF tag. These
purification protocols allowed DNA binding assays to be conducted and showed DNA binding
stayed intact. Initial SEC on DNA bound TF-MV02 shows promising results that MV02 is
similar to the other integrase and related enzymes that binds DNA and form multimeric
complexes. Our results have paved the way for further functional studies to test for DNA
processing and DNA strand transfer. In addition, the high purity protein with or without DNA
can be used for crystallization and structural determination.
Up to date, only one integrase with target DNA sequences has been structurally solved
[32]. The HIV-1 integrase is a popular target for drug development against AIDS, but no
effective drug has been developed against integrases. Solving the atomic structure of DNA
bound HIV-1 integrase proves hard to crystallize most likely due to it being part of the large preintegration complex (PIC), a complex that includes all the necessary components for HIV-1
DNA integration into host DNA [35]. Although MV02 resembles a retroviral integrase, it does
not belong to a PIC. Solving the atomic structure of an MV02/DNA complex would provide
more insight for drug development against HIV-1 integrase.
In addition, genomic sequencing studies have verified that certain strains of C.
roenbergensis have the mavirus DNA integrated into their genome even without CroV infection
occurring. Virophage DNA integration has only been observed in mavirus infection and leads to
the host C. roenbergensis becoming immune to CroV infection, resulting in mavirus infection
being greatly beneficial to the host community (Manuscript sent for review, Fischer et al.).
Studying MV02 will shed light on this complex relationship between the mavirus virophage, its
CroV host virus, and its host Cafeteria roenbergensis.

28

References
1.

Six, E.W. and C.A. Klug, Bacteriophage P4: a satellite virus depending on a helper such
as prophage P2. Virology, 1973. 51(2): p. 327-44.

2.

Kos, A., et al., The hepatitis delta (delta) virus possesses a circular RNA. Nature, 1986.
323(6088): p. 558-60.

3.

Krupovic, M., J.H. Kuhn, and M.G. Fischer, A classification system for virophages and
satellite viruses. Arch Virol, 2016. 161(1): p. 233-47.

4.

Kassanis, B., Properties and behaviour of a virus depending for its multiplication on
another. J Gen Microbiol, 1962. 27: p. 477-88.

5.

Murant, A.F. and M.A. Mayo, Satellites of Plant-Viruses. Annual Review of
Phytopathology, 1982. 20: p. 49-70.

6.

Hu, C.C., Y.H. Hsu, and N.S. Lin, Satellite RNAs and Satellite Viruses of Plants.
Viruses, 2009. 1(3): p. 1325-50.

7.

Simon, A.E., M.J. Roossinck, and Z. Havelda, Plant virus satellite and defective
interfering RNAs: new paradigms for a new century. Annu Rev Phytopathol, 2004. 42: p.
415-37.

8.

La Scola, B., et al., The virophage as a unique parasite of the giant mimivirus. Nature,
2008. 455(7209): p. 100-4.

9.

Fischer, M.G. and C.A. Suttle, A virophage at the origin of large DNA transposons.
Science, 2011. 332(6026): p. 231-4.

10.

Yau, S., et al., Virophage control of antarctic algal host-virus dynamics. Proc Natl Acad
Sci U S A, 2011. 108(15): p. 6163-8.

29

11.

Gaia, M., et al., Zamilon, a novel virophage with Mimiviridae host specificity. PLoS
One, 2014. 9(4): p. e94923.

12.

La Scola, B., et al., A giant virus in amoebae. Science, 2003. 299(5615): p. 2033.

13.

Claverie, J.M. and C. Abergel, Mimivirus: the emerging paradox of quasi-autonomous
viruses. Trends Genet, 2010. 26(10): p. 431-7.

14.

Claverie, J.M., et al., Mimivirus and the emerging concept of "giant" virus. Virus Res,
2006. 117(1): p. 133-44.

15.

Fischer, M.G., et al., Giant virus with a remarkable complement of genes infects marine
zooplankton. Proc Natl Acad Sci U S A, 2010. 107(45): p. 19508-13.

16.

Novoa, R.R., et al., Virus factories: associations of cell organelles for viral replication
and morphogenesis. Biol Cell, 2005. 97(2): p. 147-72.

17.

Fischer, M.G., Sputnik and Mavirus: more than just satellite viruses. Nat Rev Microbiol,
2012. 10(1): p. 78; author reply 78.

18.

Feschotte, C. and E.J. Pritham, Non-mammalian c-integrases are encoded by giant
transposable elements. Trends Genet, 2005. 21(10): p. 551-2.

19.

Kapitonov, V.V. and J. Jurka, Self-synthesizing DNA transposons in eukaryotes. Proc
Natl Acad Sci U S A, 2006. 103(12): p. 4540-5.

20.

Chatterjee, A.G., et al., The chromodomain of Tf1 integrase promotes binding to cDNA
and mediates target site selection. J Virol, 2009. 83(6): p. 2675-85.

21.

Engelman, A., A.B. Hickman, and R. Craigie, The core and carboxyl-terminal domains of
the integrase protein of human immunodeficiency virus type 1 each contribute to
nonspecific DNA binding. J Virol, 1994. 68(9): p. 5911-7.

30

22.

Johansson, C., M. Kamali-Moghaddam, and L. Sundstrom, Integron integrase binds to
bulged hairpin DNA. Nucleic Acids Res, 2004. 32(13): p. 4033-43.

23.

Nair, V., HIV integrase as a target for antiviral chemotherapy. Rev Med Virol, 2002.
12(3): p. 179-93.

24.

Hare, S., G.N. Maertens, and P. Cherepanov, 3'-processing and strand transfer catalysed
by retroviral integrase in crystallo. EMBO J, 2012. 31(13): p. 3020-8.

25.

Fuhrman, J.A., Marine viruses and their biogeochemical and ecological effects. Nature,
1999. 399(6736): p. 541-8.

26.

Sadir, R., et al., Characterization of the stromal cell-derived factor-1alpha-heparin
complex. J Biol Chem, 2001. 276(11): p. 8288-96.

27.

Schweppe, R.E. and A. Gutierrez-Hartmann, Pituitary Ets-1 and GABP bind to the
growth factor regulatory sites of the rat prolactin promoter. Nucleic Acids Res, 2001.
29(5): p. 1251-60.

28.

Ura, K., et al., ATP-dependent chromatin remodeling facilitates nucleotide excision
repair of UV-induced DNA lesions in synthetic dinucleosomes. EMBO J, 2001. 20(8): p.
2004-14.

29.

Lieberman, P.M. and A.J. Berk, A mechanism for TAFs in transcriptional activation:
activation domain enhancement of TFIID-TFIIA--promoter DNA complex formation.
Genes Dev, 1994. 8(9): p. 995-1006.

30.

Avila, G.A., et al., Expression and in vitro functional analyses of recombinant Gam1
protein. Protein Expr Purif, 2015. 105: p. 47-53.

31.

Maertens, G.N., S. Hare, and P. Cherepanov, The mechanism of retroviral integration
from X-ray structures of its key intermediates. Nature, 2010. 468(7321): p. 326-9.

31

32.

Montano, S.P., Y.Z. Pigli, and P.A. Rice, The mu transpososome structure sheds light on
DDE recombinase evolution. Nature, 2012. 491(7424): p. 413-7.

33.

Ferbitz, L., et al., Trigger factor in complex with the ribosome forms a molecular cradle
for nascent proteins. Nature, 2004. 431(7008): p. 590-6.

34.

Dao, V., et al., Ribosome binding of DNA analogs of tRNA requires base modifications
and supports the "extended anticodon". Proc Natl Acad Sci U S A, 1994. 91(6): p. 21259.

35.

Jaskolski, M., et al., Piecing together the structure of retroviral integrase, an important
target in AIDS therapy. FEBS J, 2009. 276(11): p. 2926-46.

32

Vita

Martin Chacon received his Bachelor of Science in Biochemistry at UTEP in 2009 with a
GPA of 3.56/4.0. During his junior year of his undergraduate studies, he joined Dr. Chuan Xiao’s
lab as an Undergraduate Research Assistant. Shortly after Martin started his research, he was
accepted to the Research Initiative for Scientific Enhancement (RISE) program that helped fund
him until he graduated with his B.S. As an undergraduate, Martin traveled to Nashville,
Tennessee to present his research at the Annual Biomedical Research Conference for Minority
Students (ABRCMS). He also presented at the UTEP Campus Office of Undergraduate Research
Initiatives (COURI) symposium multiple times. As an undergraduate, Martin volunteered to
teach high school students how to conduct research in Dr. Xiao’s laboratory under the program
Work with a Scientist (WWASP).
During Martin’s candidacy as a Master’s of Science in Chemistry, he was accepted into
the SMARTS program, where he personally mentored an undergraduate student in Dr. Xiao’s
lab. He was a teaching assistant for the Department of Chemistry at UTEP. Martin was awarded
the Dodson Research grant by the UTEP graduate school, which helped fund his research for his
Master’s thesis. Martin presented his research as a graduate student at the Border Biomedical
Research Center (BBRC) conference at UTEP, at the UTEP Graduate School conference at
UTEP, and twice at the American Society of Virology conferences, once in London, Ontario,
Canada, and the other time at Virginia Tech. He will be graduating his M.S. in Chemistry with a
4.0/4.0.

Contact Information: mcchacon2@miners.utep.edu

This thesis was typed by Martin Christopher Chacon.
33

